Combining immunotherapy with bacterial injection shows promise in treatment-refractory solid tumors
Solid tumors contain areas with low oxygen levels, known as hypoxic regions, that are associated with treatment resistance, aggressive growth and an increased risk of metastasis. In previous studies, injecting tumors with Clostridium novyi-NT, a non-toxic bacteria species that thrives in hypoxic environments, can trigger an antitumor response. A new Phase Ib trial led by Sarina Piha-Paul, M.D., combined this approach with intravenous...
Study uncovers target to overcome resistance in ARID1A-mutant cancers
Many ovarian clear cell carcinomas (OCCCs) have mutations that inactivate the ARID1A tumor suppressor and are associated with resistance to...
Novel agent restores p53 function in p53-mutated AML
Mutations of the TP53 gene are very common in leukemias and other cancers. They are predictors of poor response to therapies and are...
Specific co-mutations in KRAS-mutant NSCLC improve treatment response
Patients with KRAS-mutant non-small cell lung cancer (NSCLC) also often have co-mutations in KEAP1 and LKB1, which are associated with problems with DNA damage repair pathways, treatment resistance and reduced survival. Targeting the two main components in the DNA damage repair pathway using ATR inhibitors has emerged as a therapeutic strategy, but there currently are no biomarkers to determine which patients with NSCLC are likely to...
New-onset diabetes may serve as an early marker of pancreatic cancer
Pancreatic cancer screening is not recommended for the general population due to its low incidence, leading to later diagnoses after...
Study uncovers potential therapeutic targets for low platelet blood disorders
Thrombocytopenia is a blood disorder characterized by low levels of blood platelets. These tiny blood cells, which help with clotting, are...
Chemotherapy drives changes to the genome and clonal architecture of blood stem cells that may increase risk of secondary malignancies
Hematopoietic stem and progenitor cells (HSPCs) – a main source of blood cell production – can accumulate DNA mutations over time, which can...